Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.

Int J Mol Sci · 2021 · PMC7967241 · PMID 33803402

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a mild trendno p-value reported

A mild trend towards increased overlap of both structures after combined application of both drugs suggested mild additive or synergistic BCL-2 pathway-mediated anti-apoptotic signaling.

also in 257 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.